Cargando…

HLA-DR Presentation of the Tumor Antigen MSLN Associates with Clinical Outcome of Ovarian Cancer Patients

SIMPLE SUMMARY: The immunopeptidome represents the entirety of peptides that are presented on the surface of cells on human leukocyte antigen (HLA) molecules and are recognized by the T-cell receptors of CD4(+) and CD8(+) T-cells. Malignant cells present tumor-associated antigens essential for tumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tegeler, Christian M., Scheid, Jonas, Rammensee, Hans-Georg, Salih, Helmut R., Walz, Juliane S., Heitmann, Jonas S., Nelde, Annika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101593/ https://www.ncbi.nlm.nih.gov/pubmed/35565389 http://dx.doi.org/10.3390/cancers14092260

Ejemplares similares

HLA Evolutionary Divergence as a Prognostic Marker for AML Patients Undergoing Allogeneic Stem Cell Transplantation
por: Roerden, Malte, et al.
Publicado: (2020)

Prevalence of COVID-19-associated symptoms during acute infection in relation to SARS-CoV-2-directed humoral and cellular immune responses in a mild-diseased convalescent cohort
por: Tegeler, Christian M., et al.
Publicado: (2022)

Elevated SARS-CoV-2-Specific Antibody Levels in Patients with Post-COVID Syndrome
por: Hackenbruch, Christopher, et al.
Publicado: (2023)

Upstream open reading frames regulate translation of cancer-associated transcripts and encode HLA-presented immunogenic tumor antigens
por: Nelde, Annika, et al.
Publicado: (2022)

The Peptide Vaccine of the Future
por: Nelde, Annika, et al.
Publicado: (2021)

Immunopeptidome Diversity in Chronic Lymphocytic Leukemia Identifies Patients with Favorable Disease Outcome
por: Marconato, Maddalena, et al.
Publicado: (2022)

Long-Term Follow-Up of COVID-19 Convalescents—Immune Response Associated with Reinfection Rate and Symptoms
por: Seller, Anna, et al.
Publicado: (2023)

T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals
por: Bilich, Tatjana, et al.
Publicado: (2021)

Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma
por: Bilich, Tatjana, et al.
Publicado: (2020)

TOF(IMS) mass spectrometry-based immunopeptidomics refines tumor antigen identification
por: Hoenisch Gravel, Naomi, et al.
Publicado: (2023)

Increased soluble HLA in COVID-19 present a disease-related, diverse immunopeptidome associated with T cell immunity
por: Nelde, Annika, et al.
Publicado: (2022)

Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia
por: Nelde, Annika, et al.
Publicado: (2021)

Antigen Targets for the Development of Immunotherapies in Leukemia
por: Bauer, Jens, et al.
Publicado: (2019)

Cancer testis antigen Cyclin A1 harbors several HLA-A*02:01-restricted T cell epitopes, which are presented and recognized in vivo
por: Teck, Anja Tatjana, et al.
Publicado: (2020)

Immunoprecipitation methods impact the peptide repertoire in immunopeptidomics
por: Wacker, Marcel, et al.
Publicado: (2023)

Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models
por: Schoutrop, Esther, et al.
Publicado: (2023)

Correction to: Cancer testis antigen Cyclin A1 harbors several HLA‑A*02:01‑restricted T cell epitopes, which are presented and recognized in vivo
por: Teck, Anja Tatjana, et al.
Publicado: (2021)

SARS‐CoV‐2‐reactive T‐cell receptors isolated from convalescent COVID‐19 patients confer potent T‐cell effector function
por: Brunk, Fabian, et al.
Publicado: (2021)

HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy
por: Nelde, Annika, et al.
Publicado: (2016)

Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality
por: Schoutrop, Esther, et al.
Publicado: (2022)

MSLN Correlates With Immune Infiltration and Chemoresistance as a Prognostic Biomarker in Ovarian Cancer
por: Li, Yike, et al.
Publicado: (2022)

A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and “pan-leukemia” antigens
por: Backert, Linus, et al.
Publicado: (2017)

The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma
por: Bauer, Jens, et al.
Publicado: (2022)

Neoantigens in Hematological Malignancies—Ultimate Targets for Immunotherapy?
por: Roerden, Malte, et al.
Publicado: (2019)

Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma
por: Heitmann, Jonas S, et al.
Publicado: (2020)

Neutralization of B-Cell Activating Factor (BAFF) by Belimumab Reinforces Small Molecule Inhibitor Treatment in Chronic Lymphocytic Leukemia
por: Tandler, Claudia, et al.
Publicado: (2020)

Tandem CAR-T cells targeting FOLR1 and MSLN enhance the antitumor effects in ovarian cancer
por: Liang, Zhen, et al.
Publicado: (2021)

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency
por: Heitmann, Jonas S., et al.
Publicado: (2023)

HLA ligandome tumor antigen discovery for personalized vaccine approach
por: Rammensee, Hans-Georg, et al.
Publicado: (2013)

A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity
por: Heitmann, Jonas S., et al.
Publicado: (2021)

Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy
por: Reustle, Anna, et al.
Publicado: (2020)

Metformin Antagonizes Ovarian Cancer Cells Malignancy Through MSLN Mediated IL-6/STAT3 Signaling
por: Yang, Xu, et al.
Publicado: (2021)

Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini
por: Kowalewski, D J, et al.
Publicado: (2016)

HLA-DR(+) leukocytes acquire CD1 antigens in embryonic and fetal human skin and contain functional antigen-presenting cells
por: Schuster, Christopher, et al.
Publicado: (2009)

Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies
por: Kauer, Joseph, et al.
Publicado: (2020)

A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer
por: Deng, Li, et al.
Publicado: (2012)

A NOVEL MSLN×4-1BB BISPECIFIC ANTIBODY FOR SOLID TUMOR
por: Cheng, Liansheng, et al.
Publicado: (2023)

The role of polymorphic HLA-DR beta chain residues in presentation of viral antigens to T cells
Publicado: (1990)

Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs
Publicado: (1996)

Fibrillary Glomerulonephritis Is Associated With HLA-DR7 and HLA-B35 Antigens
por: Andeen, Nicole K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_43jlrhbic6bac2fpmc6sjk4chp